Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood. The company is also developing autologous stem cell-based therapies that address medical needs for applications in the vascular, cardiology, and orthopedic markets. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California. Cesca Therapeutics Inc. is a subsidiary of Boyalife (Hong Kong) Limited.
Industry, Sector and Symbol
Industry Laboratory apparatus & furniture
Sub-IndustryN/A
SectorMedical
Phone916-858-5100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$14.52 million
Profitability
Miscellaneous
Employees70
OptionableNot Optionable
Cesca Therapeutics (NASDAQ:KOOL) Frequently Asked Questions
What is Cesca Therapeutics' stock symbol?
Cesca Therapeutics trades on the NASDAQ under the ticker symbol "KOOL."
How were Cesca Therapeutics' earnings last quarter?
Cesca Therapeutics Inc (NASDAQ:KOOL) posted its quarterly earnings data on Wednesday, November, 14th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.02. The biotechnology company had revenue of $3.11 million for the quarter, compared to analysts' expectations of $2.97 million. Cesca Therapeutics had a negative net margin of 323.73% and a negative return on equity of 22.66%. View Cesca Therapeutics' Earnings History.
When is Cesca Therapeutics' next earnings date?
What price target have analysts set for KOOL?
1 Wall Street analysts have issued twelve-month target prices for Cesca Therapeutics' shares. Their predictions range from $2.00 to $2.00. On average, they expect Cesca Therapeutics' stock price to reach $2.00 in the next year. This suggests a possible upside of 564.5% from the stock's current price. View Analyst Price Targets for Cesca Therapeutics.
What is the consensus analysts' recommendation for Cesca Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cesca Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cesca Therapeutics.
Has Cesca Therapeutics been receiving favorable news coverage?
News stories about KOOL stock have trended very positive on Monday, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cesca Therapeutics earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are some of Cesca Therapeutics' key competitors?
Some companies that are related to Cesca Therapeutics include Ceapro (CRPOF), HedgePath Pharmaceuticals (HPPI), PAVmed (PAVM), Streamline Health Solutions (STRM), Aethlon Medical (AEMD), OvaScience (OVAS), ESSA Pharma (EPIX), Provectus Biopharmaceuticals (PVCT), Trillium Therapeutics (TRIL), Advaxis (ADXS), Acerus Pharmaceuticals (TRLPF), GTX (GTXI), Biocorrx (BICX), Genprex (GNPX) and Biomerica (BMRA).
Who are Cesca Therapeutics' key executives?
Cesca Therapeutics' management team includes the folowing people:
- Mr. Jeff Cauble, Principal Financial & Accounting Officer (Age 46)
- Mr. James Xu, Director, Gen. Counsel & Sr. VP of Legal Affairs (Age 48)
- Dr. Xiaochun Xu Ph.D., Chairman & CEO (Age 48)
- Mr. Philip H. Coelho, Chief Technology Officer (Age 75)
- Ms. Haihong Zhu, Pres of ThermoGenesis
How do I buy shares of Cesca Therapeutics?
Shares of KOOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cesca Therapeutics' stock price today?
One share of KOOL stock can currently be purchased for approximately $0.3010.
How big of a company is Cesca Therapeutics?
Cesca Therapeutics has a market capitalization of $6.52 million and generates $14.52 million in revenue each year. Cesca Therapeutics employs 70 workers across the globe.
What is Cesca Therapeutics' official website?
How can I contact Cesca Therapeutics?
Cesca Therapeutics' mailing address is 2711 CITRUS ROAD, RANCHO CORDOVA CA, 95742. The biotechnology company can be reached via phone at 916-858-5100 or via email at [email protected]
MarketBeat Community Rating for Cesca Therapeutics (NASDAQ KOOL)
MarketBeat's community ratings are surveys of what our community members think about Cesca Therapeutics and other stocks. Vote "Outperform" if you believe KOOL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KOOL will underperform the S&P 500 over the long term. You may vote once every thirty days.
